8月4日，金斯瑞生物科技盘中上涨5.15%，报17.62港元，成交额1.0亿港元。
消息面上，公司联营公司传奇生物此前披露，CARVYKTI于截至6月30日止季度产生贸易销售净额约6.57亿美元，同比增长近五成，延续强劲增长态势。该销售数据由合作伙伴Janssen Biotech根据双方合作及许可协议提供。此外，传奇生物在研体内CD19/CD20双靶点CAR-T疗法LB2501在复发/难治性B细胞非霍奇金淋巴瘤I期研究中达到100%客观缓解率，管线进展积极，多重利好叠加持续推动股价走强。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.